127 related articles for article (PubMed ID: 21416695)
21. [Updated treatment of primary pulmonary hypertension -- the role of endothelin receptor antagonists].
Callejas Rubio JL; Ortego Centeno N; Navarro Pelayo F; Vallejo Rodríguez I
Farm Hosp; 2004; 28(4):294-5. PubMed ID: 15369441
[No Abstract] [Full Text] [Related]
22. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
Cacoub P; Amoura Z; Langleben D
Rev Med Interne; 2008 Apr; 29(4):283-9. PubMed ID: 18243424
[TBL] [Abstract][Full Text] [Related]
23. Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension.
Pulido T; Sandoval J; Roquet I; Gutiérrez R; Rueda T; Peña H; Santos E; Miranda MT; Lupi E
Eur J Clin Invest; 2009 Jun; 39 Suppl 2():14-8. PubMed ID: 19335742
[TBL] [Abstract][Full Text] [Related]
24. Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
Faruqi S; Fathi H; Morice AH
Int J Cardiol; 2010 Oct; 144(3):e43-5. PubMed ID: 19171388
[TBL] [Abstract][Full Text] [Related]
25. Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.
Widlitz AC; Barst RJ; Horn EM
Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):985-91. PubMed ID: 16292989
[TBL] [Abstract][Full Text] [Related]
26. [Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension].
Ghofrani HA
Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S177-8. PubMed ID: 19718611
[No Abstract] [Full Text] [Related]
27. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
Hoeper MM
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
[TBL] [Abstract][Full Text] [Related]
28. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
Langleben D; Cacoub P
Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of sitaxentan (Thelin®) toxicity in juvenile rats and regulatory interactions during the development of a European Medicines Agency pediatric investigation plan.
Cross DM; Derzi M; Horsley E; Owen K; Stavros FL
Regul Toxicol Pharmacol; 2012 Oct; 64(1):43-50. PubMed ID: 22683288
[TBL] [Abstract][Full Text] [Related]
30. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
[TBL] [Abstract][Full Text] [Related]
31. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
Mucke HA
IDrugs; 2009 Jun; 12(6):366-75. PubMed ID: 19517317
[TBL] [Abstract][Full Text] [Related]
32. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.
Ben-Yehuda O; Pizzuti D; Brown A; Littman M; Gillies H; Henig N; Peschel T
J Am Coll Cardiol; 2012 Jul; 60(1):80-1. PubMed ID: 22578922
[No Abstract] [Full Text] [Related]
33. Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.
Sandoval J; Torbicki A; Souza R; Ramírez A; Kurzyna M; Jardim C; Jerjes-Sánchez Díaz C; Teal SA; Hwang LJ; Pulido T;
Pulm Pharmacol Ther; 2012 Feb; 25(1):33-9. PubMed ID: 22079088
[TBL] [Abstract][Full Text] [Related]
34. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
O'Callaghan DS; Gaine SP
Int J Clin Pract; 2006 Apr; 60(4):475-81. PubMed ID: 16620363
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan.
Kähler CM; Graziadei I; Vogelsinger H; Desole S; Cima K; Vogel W
Wien Klin Wochenschr; 2011 Apr; 123(7-8):248-52. PubMed ID: 21451953
[TBL] [Abstract][Full Text] [Related]
36. Endothelin antagonism in pulmonary arterial hypertension.
Lee SH; Channick RN
Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317
[TBL] [Abstract][Full Text] [Related]
37. Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition.
Luo N; Ryan JJ
Can J Cardiol; 2013 Jun; 29(6):659-61. PubMed ID: 22985784
[No Abstract] [Full Text] [Related]
38. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.
Waxman AB
Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185
[TBL] [Abstract][Full Text] [Related]
39. [Clinical progress of endothelin receptor antagonists therapy for pulmonary arterial hypertension(no abstract).].
Xu XQ; Zhang JH; Jing ZC
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Oct; 36(10):951-3. PubMed ID: 19102901
[No Abstract] [Full Text] [Related]
40. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
Valerio CJ; Handler CE; Kabunga P; Smith CJ; Denton CP; Coghlan JG
Rheumatology (Oxford); 2010 Nov; 49(11):2147-53. PubMed ID: 20675359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
